Switzerland Archives

News and Trends 20 Oct 2016

CRISPR Thx’ surprisingly low IPO… why are Investors Discouraged?

Troubled waters in the CRISPR field: CRISPR Therapeutics’ IPO hits an unexpectedly low price. It seems that the investors are starting to switch from hype to uncertainty, but why now? CRISPR Therapeutics has just announced the results of a surprisingly low IPO: €51M ($56M), way lower than its €80M target. Its competitors in the therapeutics CRISPR field, Editas […]

October 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2016

And the highest funding in Europe this year goes to… Antibody-Drug Conjugates!

AstraZeneca has contributed to ADC Therapeutics’ €96M fundraising, the biggest round so far in Europe this year. Will this huge investment pay out for the British-Swedish Big Pharma? ADC Therapeutics (ADCT) is a Swiss Biotech that develops antibody-drug conjugates (ADCs) for oncology applications. Its founder Auven Therapeutics and its partner AstraZeneca have participated in the biggest […]

October 19, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 09 29 at 4.53.52 PM e1475160985987

News and Trends 30 Sep 2016

Tailored Cancer Vaccines? NousCom is working on it!

We aren’t leaving Switzerland yet! We took a scenic train to Basel in order to meet nousCom, a very young biotech developing cancer vaccines. City: Basel, Switzerland Founded: 2015 Employees: unknown Financial Data: €12M raised in series A Mission: NousCom is a Biotech that develops next generation cancer vaccines with patient- and tumor-specific antigens. Their vaccines combine viruses […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 30 Sep 2016

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company’s CFO, who explained its advantageous position against big pharma. GeNeuro raised €33M in its Euronext IPO in April and is currently competing against giants like Novartis and Biogen. Despite 2016’s dubious honor as “the worst year for IPO in 20 years”, this Switzerland-based company has managed to go […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 29 Sep 2016

Interview: This Biotech Could Have the First HIV Cure on the Market

InnaVirVax is one of the most advanced companies in the race to develop an HIV cure. At the SACHS Conference in Basel, we had the opportunity to pick the brain of the CEO, Joël Crouzet, about his company’s progress. Last week, we reviewed progress in biotech towards an HIV cure, which could hit the market […]

September 29, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 28 Sep 2016

ITW: Prexton Therapeutics CEO explains Development of new Parkinson’s Drug

For our first interview at the SACHS Conference in Basel yesterday, I met with François Conquet, founder and CEO of Prexton Therapeutics. His company’s treatment for Parkinson’s Disease just passed Phase I with flying colors. Prexton Therapeutics, based in Switzerland, has been focused on discovering new small molecules to treat Parkinson’s, and one of them, an mGluR4 positive […]

September 28, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 26 Sep 2016

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

It’s not the $700M headlines imply, but AC Immune is winding up to make a splashy IPO of €52.5M to establish itself in the Alzheimer’s Disease space. You might have read about AC Immune‘s ‘$700M IPO’ and thought, “gee, that can’t be right – that sum is roughly half of the total from all European companies […]

September 26, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 26 Sep 2016

Terrible Turing hasn’t given up on Toxoplasmosis (or its Karma)

The biopharmaceutical company’s Swiss division just published computational studies aiming to improve Daraprim, after its former CEO, Martin Shkreli, attempted to justify the scandalous 5000% price hike as a boost for its R&D. A little over a year ago, Martin Shkreli, founder and then-CEO of Turing Pharmaceuticals, hiked the price of a common medication for toxoplasmosis by […]

September 26, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 23 Sep 2016

SELLAS wants to sell us an Immunotherapy for Mesothelioma

After Cyprus, we mosey back to the mainland to visit the country gave the world the cuckoo clock. That’s right, we’re Schweiz-bound. In Switzerland, we’ll meet an immuno-oncology biotech, SELLAS Life Sciences. City: Zug (Zurich-area), Switzerland Founded: 2012 Employees: 11 – 50 Financial Data: None available…what a secretive cohort. Mission: SELLAS Life Sciences is a development-stage biopharmaceutical company focused on […]

September 23, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 20 Sep 2016

UPDATE: Novartis is Favoured to Win the Race for a New MS Drug

Novartis is poised to kick off the next generation of multiple sclerosis treatments after siponimod performs well in Phase III. The company’s primary competitor had been Biogen, but its drug’s failure in Phase II leaves siponimod the last man standing. Novartis reports that its multiple sclerosis (MS) drug, siponimod, has reached its primary endpoint in Phase III […]

September 20, 2016 - 2 minutesmins - By Evelyn Warner

multiple sclerosis by decade3d anatomy online FI

News and Trends 15 Sep 2016

Roche’s New Antibody is besting the best MS Drug

Roche is poised to blow away the competition for the new multiple sclerosis drug with its leading candidate, Ocrevus (ocrelizumab). Phase III data shows it outperforming Merck’s Rebif, the standard therapy for MS. Competition for a new MS drug has been stiff, but new promising data from the Phase III trial of Ocrevus (ocrelizumab) suggests […]

September 15, 2016 - 2 minutesmins - By Evelyn Warner

philippe dro serial biotech entrepreneur

News and Trends 14 Sep 2016

How to be a Serial Biotech Entrepreneur in Europe with Philippe Dro

Not many people are as successful as entrepreneur Philippe Dro: he is one of the very few serial Biotech entrepreneurs in Europe. He is a founder or early backer of three Biotech or Medtech companies that have since been acquired by big Pharma, all in less just 15 years! I had a nice chat with Dro […]

September 14, 2016 - 5 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Switzerland

CRISPR Thx’ surprisingly low IPO… why are Investors Discouraged?

And the highest funding in Europe this year goes to… Antibody-Drug Conjugates!

Tailored Cancer Vaccines? NousCom is working on it!

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

Interview: This Biotech Could Have the First HIV Cure on the Market

ITW: Prexton Therapeutics CEO explains Development of new Parkinson’s Drug

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

Terrible Turing hasn’t given up on Toxoplasmosis (or its Karma)

SELLAS wants to sell us an Immunotherapy for Mesothelioma

UPDATE: Novartis is Favoured to Win the Race for a New MS Drug

Roche’s New Antibody is besting the best MS Drug

How to be a Serial Biotech Entrepreneur in Europe with Philippe Dro

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!